drugset
drugset / Trial / NCT04368507

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

NCT04368507 ↗

Phase 1/2 Completed 35 enrolled CellabMED Yooyoung Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of YYB101 with Irinotecan, patients who are metastatic or recurrent Colorectal Cancer Patients.

Timeline

Start
2019-08-09
Primary completion
2021-12-21
Completion
2021-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject UMIKIBART Monoclonal antibody 20 mg/kg Intravenous
Background Irinotecan Small molecule 150 mg/m2 Intravenous

Indications

colorectal cancer